Shaun M. Van Horn

I'll verify this attorney's background and case history before drafting.

Let me dig into the specific litigation and PTAB activity.

Shaun M. Van Horn — Patent Litigation Practice Summary

Specialty / focus. Van Horn's patent practice is concentrated in life sciences — specifically biologics and biosimilars litigation under the BPCIA, along with Hatch-Waxman/ANDA-adjacent work. His technical background is in molecular biology and biochemistry: firm bios cite recombinant technology, cell line development, protein dynamics, genetic engineering, oncology, immunology, and chromatography/purification, with additional small-molecule drug experience. A second, distinctive strand of his practice is the antitrust/IP interface — licensing disputes, pay-for-delay issues, and IP-related competition claims — and he co-authored the ABA Intellectual Property Law Section treatise Antitrust Issues in Intellectual Property Law (2016). There is no indication of Wi-Fi/standards, software, or mechanical patent work; his matters also frequently involve cross-border and multi-jurisdictional disputes.

Side preference. He is predominantly a defense-side litigator, consistent with the tracked record (0 plaintiff / 2 defendant appearances). Both tracked matters involve him representing biosimilar developers — Formycon AG and Samsung Bioepis — against innovator Regeneron in the aflibercept (Eylea) litigation. His broader practice is not exclusively defense-oriented in the antitrust/commercial space, and his Jenner bio also cites representing an innovator small-molecule developer in a Delaware trade-secret action, but the patent-biosimilar work is squarely client-side defense.

Firm context. He is currently a Partner at Jenner & Block in Chicago, having returned to the firm on September 25, 2025, to its Business Litigation and Antitrust & Competition Law practices — his second stint after roughly 15 years there. In between (February 2024–2025) he was at Fish & Richardson as a Principal in the Litigation Group and Life Sciences Industry Team, joining alongside Louis Fogel and providing momentum for Fish's Chicago office. The tracked appearances map onto that timeline: the Formycon matter is attributed to Fish & Richardson, and the Samsung Bioepis matter to Jenner & Block. Note a data caveat: the underlying case list labels him "Of Counsel" in the Jenner matter and lists three firm entries across only two cases, which is inconsistent with public reporting that he held partner-level titles (Partner at Jenner; Principal at Fish). Treat the firm/role tags as approximate.

Notable cases. Both tracked cases are part of Regeneron's aflibercept biosimilar MDL in the N.D. W. Va. (No. 1:24-md-03103), where Regeneron asserted roughly 40 patents running as late as 2040. In Regeneron v. Formycon, the court granted Regeneron a preliminary injunction (June/July 2024), which the Federal Circuit affirmed in January 2025 — an adverse interim result for the defense; the case then settled on September 29, 2025, with all claims dismissed and the injunction vacated, and Formycon's Ahzantive cleared for U.S. launch in Q4 2026. Similarly, in Regeneron v. Samsung Bioepis, the district court enjoined Samsung Bioepis in June 2024 on U.S. Patent No. 11,084,865, and the Federal Circuit affirmed on January 29, 2025; the parties settled on February 11, 2026, with the injunction vacated and Samsung Bioepis permitted to launch Opuviz in the U.S. from January 2027. His Jenner profile also lists a BPCIA "patent dance" and Delaware infringement action concerning a leading oncology drug, and an antitrust defense role in In re CRT Antitrust Litigation and In re Auto Parts Antitrust Litigation. I could not verify from public sources whether he personally argued the Federal Circuit appeals, so I have not credited him with those outcomes beyond his team's involvement.

PTAB / IPR. IPR work appears in his practice description — Jenner's bio states he assists clients with inter partes reviews and cites a biosimilar-company IPR concerning an anti-inflammatory drug formulation — but I found no evidence that he is a registered practitioner or a routine lead counsel in PTAB proceedings. Separate IPR petitions in the aflibercept MDL (e.g., by Mylan and Fresenius) are attributable to other parties' counsel, not to him.

Bar / education. J.D., New York University School of Law (2008; Robert McKay Scholar); undergraduate degree in biochemistry (Fish press release) from the University of Michigan (Jenner bio lists a 2005 degree there; B.A. vs. B.S. is reported inconsistently). A court-admission listing for the U.S. District Court for the Northern District of Illinois (2008) appears in his Jenner bio; his Illinois bar admission is not independently confirmed in the sources reviewed.